Crispr/cas-related methods and compositions for knocking out c5
US-2024415980-A1 · Dec 19, 2024 · US
US12105087B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12105087-B2 |
| Application number | US-201716467116-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 11, 2017 |
| Priority date | Dec 9, 2016 |
| Publication date | Oct 1, 2024 |
| Grant date | Oct 1, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention includes an ex-situ biosensors that impedimetrically detect one or more target biomarkers of brain injury or disease in a bodily fluid sample derived from a patient. The biosensors include a multi-array of vertically aligned platinum wires having immobilized thereon antibody and/or aptamer that specifically and selectively bind to the one or more target biomarkers. An electrochemical impedance signal is generated, and a change in electrochemical impedance is indicative of the presence of the one or more target biomarker(s) in the bodily fluid sample. The biosensors are point-of-care, on-demand devices useful in a medical and domestic environment.
Opening claim text (preview).
The invention claimed is: 1. A portable, ex-situ system to impedimetrically detect one or more target biomarkers related to brain injury or disease in a bodily fluid sample of a patient, comprising: a conducting material interface, comprising: an epoxy resin; and a multi-array of vertically aligned conducting metal wires selected from the group consisting of platinum wires, gold wires, iridium wires, ruthenium wires, palladium wires, osmium wires, and alloys and combinations thereof, each of the plurality of conducting metal wires having a first end and an opposite second end with the first end cast in the epoxy resin; a thiol-based compound applied to the second end of the plurality of conducting wires to form a thiol treated surface; an immobilization agent applied to the thiol treated surface; and at least one biotinylated antibody and/or aptamer applied to the immobilization agent, selected to bind with the immobilization agent and the one or more target biomarkers related to brain injury or disease; a signaling agent comprising an electrochemical impedance signal generated by binding of the at least one biotinylated antibody and/or aptamer with the one or more target biomarkers related to brain injury or disease; and the bodily fluid sample derived from the patient and in contact with the at least one biotinylated antibody and/or aptamer to detect the one or more target biomarkers related to brain injury or disease, wherein the system is structured such that in its use a change in electrochemical impedance indicates a presence of the one or more target biomarkers related to brain injury or disease in the bodily fluid sample and binding of the at least one biotinylated antibody and/or aptamer with the one or more target biomarkers in the bodily fluid sample, and wherein the system is structured such that in its use an absence of a change in electrochemical impedance indicates an absence of the one or more target biomarkers related to brain injury or disease in the bodily fluid sample. 2. The system of claim 1 , wherein the bodily fluid sample is a blood sample. 3. The system of claim 1 , wherein the one or more target biomarkers related to brain injury or disease are selected from the group consisting of Tau proteins, Glial Fibrilar Acidic Protein (GFAP) and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1). 4. The system of claim 1 , wherein the immobilization agent is selected from the group consisting of avidin, streptavidin, neutravidin and mixtures thereof. 5. The system of claim 1 , wherein the antibody and/or aptamer sensor is effective to impedimetrically detect simultaneously a plurality of target biomarkers related to brain injury or disease in the bodily fluid sample. 6. The system of claim 1 , wherein the multi-array of vertically aligned conducting material wires are arranged in a concentric configuration.
Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event · CPC title
Electrodes · CPC title
Investigating or analysing materials by the use of electric, electrochemical, or magnetic means (G01N3/00 – G01N25/00 take precedence; measurement or testing of electric or magnetic variables or of electric or magnetic properties of materials G01R) · CPC title
related to diseases not provided for elsewhere · CPC title
against material from animals or humans · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.